{"id":"https://openalex.org/W1915345708","doi":null,"title":"Omalizumab and malignancy: Interim results from the EXCELS study","display_name":"Omalizumab and malignancy: Interim results from the EXCELS study","alternate_titles":[],"publication_year":2011,"publication_date":"2011-09-01","ids":{"openalex":"https://openalex.org/W1915345708","mag":"1915345708"},"language":"en","primary_location":{"id":"mag:1915345708","doi":null,"is_oa":false,"landing_page_url":"http://erj.ersjournals.com/content/38/Suppl_55/p3954","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"European Respiratory Journal","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W1915345708"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029006978","display_name":"Mark D. Eisner","orcid":"https://orcid.org/0000-0003-4849-6618","observed_orcids":["https://orcid.org/0000-0003-4849-6618"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark D. Eisner","raw_affiliation_strings":["Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States"],"raw_orcid":"https://orcid.org/0000-0003-4849-6618","affiliations":[{"raw_affiliation_string":"Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109329978","display_name":"Mary Katherine Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary K. Miller","raw_affiliation_strings":["Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109219298","display_name":"Will Chou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Will Chou","raw_affiliation_strings":["Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065626751","display_name":"Abdelkader Rahmaoui","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdelkader Rahmaoui","raw_affiliation_strings":["Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108379338","display_name":"Mary S. Bradley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mary S. Bradley","raw_affiliation_strings":["Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Global Product Development - Inflammation & Respiratory, Genentech Inc., South San Francisco, CA, United States","institution_ids":["https://openalex.org/I183934855"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I183934855"],"apc_list":null,"apc_paid":null,"fwci":0.9825,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.77969123,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"38","issue":null,"first_page":"3954","last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.9545999765396118,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.03610000014305115,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10877","display_name":"Allergic Rhinitis and Sensitization","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/omalizumab","display_name":"omalizumab","score":1.0},{"id":"https://openalex.org/keywords/malignancy-incidence","display_name":"malignancy incidence","score":0.8090000152587891},{"id":"https://openalex.org/keywords/allergic-asthma","display_name":"allergic asthma","score":0.8759999871253967},{"id":"https://openalex.org/keywords/long-term-drug-safety","display_name":"long-term drug safety","score":0.718999981880188},{"id":"https://openalex.org/keywords/anti-ige-therapy","display_name":"anti-IgE therapy","score":0.8169999718666077},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.6299999952316284},{"id":"https://openalex.org/keywords/primary-malignancy","display_name":"primary malignancy","score":0.5249999761581421},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.4099999964237213}],"concepts":[{"id":"https://openalex.org/C2778564945","wikidata":"https://www.wikidata.org/wiki/Q415392","display_name":"Omalizumab","level":4,"score":0.9880475997924805},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9538142681121826},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.6731734275817871},{"id":"https://openalex.org/C61511704","wikidata":"https://www.wikidata.org/wiki/Q1671857","display_name":"Incidence (geometry)","level":2,"score":0.6639577150344849},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.6220437288284302},{"id":"https://openalex.org/C2776957806","wikidata":"https://www.wikidata.org/wiki/Q4895105","display_name":"Interim","level":2,"score":0.5347496867179871},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5272815823554993},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5145896673202515},{"id":"https://openalex.org/C2776042228","wikidata":"https://www.wikidata.org/wiki/Q35869","display_name":"Asthma","level":2,"score":0.47283515334129333},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.44261133670806885},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.41680198907852173},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3849028944969177},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.33263951539993286},{"id":"https://openalex.org/C141105273","wikidata":"https://www.wikidata.org/wiki/Q79455","display_name":"Immunoglobulin E","level":3,"score":0.1270788609981537},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.1074407696723938},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.09697127342224121},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.09249681234359741},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.06621944904327393},{"id":"https://openalex.org/C120665830","wikidata":"https://www.wikidata.org/wiki/Q14620","display_name":"Optics","level":1,"score":0.0},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C95457728","wikidata":"https://www.wikidata.org/wiki/Q309","display_name":"History","level":0,"score":0.0},{"id":"https://openalex.org/C166957645","wikidata":"https://www.wikidata.org/wiki/Q23498","display_name":"Archaeology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:1915345708","doi":null,"is_oa":false,"landing_page_url":"http://erj.ersjournals.com/content/38/Suppl_55/p3954","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"European Respiratory Journal","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2066531673","https://openalex.org/W4392640667","https://openalex.org/W2076390297","https://openalex.org/W2412568036","https://openalex.org/W2572238246","https://openalex.org/W2151135346","https://openalex.org/W2330424086","https://openalex.org/W2957504595","https://openalex.org/W1966079364","https://openalex.org/W2314741088"],"abstract_inverted_index":{"Background:":[0],"Omalizumab":[2],"is":[3,15,55,72,231,237],"a":[4,191],"biologic":[5],"for":[6,100],"the":[7,22,27,62,149,156,182,185,211,218,229,235],"treatment":[8],"of":[9,24,29,65,78,131,165,170,194,213],"moderate-to-severe":[10,85],"persistent":[11,86],"allergic":[12,87],"asthma":[13,88],"that":[14],"inadequately":[16],"controlled":[17],"with":[18],"inhaled":[19],"corticosteroids.":[20],"At":[21],"time":[23],"FDA":[25,57],"approval,":[26],"incidence":[28,169,212],"malignant":[30],"neoplasms":[31],"was":[32,134,174,215],"higher":[33],"among":[34],"patients":[35,89],"who":[36,97],"had":[37,161],"received":[38],"omalizumab":[39,150,183,219],"(0.5%)":[40],"compared":[41],"to":[42,60,102,190,202],"placebo":[43],"(0.2%)":[44],"in":[45,148,155,181,217],"clinical":[46],"trials.":[47],"Objective:":[50],"The":[52,116,168],"EXCELS":[53,71],"study":[54,77,138,230,236],"an":[56,73,112,162],"postmarketing":[58],"commitment":[59],"evaluate":[61],"long-term":[63],"safety":[64],"omalizumab.":[66],"Methods:":[69],"ongoing":[74],"prospective":[75],"observational":[76],"approximately":[79],"5000":[80],"omalizumab-treated":[81],"and":[82,152,176,184,220,228,240,251],"2500":[83],"non-omalizumab-treated":[84],"aged":[90],"\u226512":[91],"years":[92],"from":[93],"448":[94],"US":[95],"centers":[96],"are":[98,109,226],"followed":[99],"up":[101],"5":[103],"years.":[104],"All":[105],"reported":[106],"potential":[107],"malignancies":[108],"reviewed":[110],"by":[111],"independent":[113],"oncology":[114],"panel.":[115],"primary":[117,123,172],"analysis":[118,130],"includes":[119],"confirmed,":[120],"incident":[121],"study-emergent":[122,171],"malignancies.":[124],"Results:":[127],"This":[129],"malignancy":[132,173,214],"rates":[133],"based":[135],"on":[136],"interim":[137,224],"report":[139],"6":[140],"(data":[141],"through":[142],"11/30/2010)":[143],"which":[144],"comprises":[145],"18,860":[146],"person-years":[147,154,180,198],"cohort":[151],"10,947":[153],"non-omalizumab":[157,186,221],"cohort.":[158],"Both":[159],"cohorts":[160],"average":[163],"follow-up":[164],"3.8":[166],"person-years.":[167],"12.78":[175],"14.48":[177],"per":[178,196],"1000":[179,197],"cohorts,":[187],"respectively,":[188],"corresponding":[189],"rate":[192],"difference":[193],"-1.70":[195],"(95%":[199],"CI:":[200],"-6.43":[201],"2.21).":[203],"Conclusions:":[206],"In":[208],"this":[209],"analysis,":[210],"similar":[216],"cohorts.":[222],"These":[223],"results":[225],"preliminary":[227],"still":[232],"ongoing.":[233],"Because":[234],"observational,":[238],"selection":[239],"other":[241],"biases":[242],"cannot":[243],"be":[244],"excluded.":[245],"Funding":[247],"Source:":[248],"Genentech,":[249],"Inc":[250],"Novartis":[252],"Pharmaceuticals":[253],"Corp.":[254]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1915345708","counts_by_year":[{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}
